The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma
Open accessAbstract
Background and Aims: The outcome of patients with hepatocellular carcinoma (HCC) remains poor because of late diagnosis. The aim of this study was to compare the accuracy of alpha fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in the early diagnosis of HCC. Methods: Among 1031 patients randomized in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial, a nested case-control study of 39 HCC cases (24 early stage) and 77 matched controls was conducted to compare the performance of AFP and DCP. Testing was performed on sera from 12 months prior (month −12) to the time of HCC diagnosis (month 0). Results: The sensitivity and specificity of DCP at month 0 was 74% and 86% at a cutoff of 40 mAU/mL and 43% and 100% at a cutoff of 150 mAU/mL. The sensitivity and specificity of AFP at month 0 was 61% and 81% at a cutoff of 20 ng/mL and 22% and 100% at a cutoff of 200 ng/mL. At month −12, the sensitivity and specificity at the low cutoff was 43% and 94% for DCP and 47% and 75% for AFP. Combining both markers increased the sensitivity to 91% at month 0 and 73% at month 12 but the specificity decreased to 74% and 71%. Diagnosis of early HCC was triggered by surveillance ultrasound in 14, doubling of AFP in 5 and combination of tests in 5 patients. Conclusions: Biomarkers are needed to complement ultrasound in the detection of early HCC but neither DCP nor AFP is optimal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Randomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496
Hepatocellular carcinoma: Recent trends in the United States
El-Serag, H. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.013 · Cited by 972
Lok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., Bonkovsky, H. L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.014 · Cited by 651
Self-citationBolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., Piscaglia, F., Gramantieri, L., Zanetti, M., & Sherman, M. (2001) · Gut · doi:10.1136/gut.48.2.251 · Cited by 643
Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma
Liebman, H. A., Furie, B. C., Tong, M. J., Blanchard, R. A., Lo, K.-J., Lee, S.-D., Coleman, M. S., & Furie, B. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405313102204 · Cited by 617
Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707615 · Cited by 465
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Metadata
- Authors
- Lok, A. S., Sterling, R. K., Everhart, J. E., Wright, E. C., Hoefs, J. C., Di Bisceglie, A. M., Morgan, T. R., Kim, H., Lee, W. M., Bonkovsky, H. L., & Dienstag, J. L.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 138
- Issue
- 2
- Pages
- 493-502
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2000001318
- Cited by
- 558
- References
- 28
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1053/j.gastro.2009.10.031
- The paper
- Lok, A. S., Sterling, R. K., Everhart, J. E., Wright, E. C., Hoefs, J. C., Di Bisceglie, A. M., Morgan, T. R., Kim, H., Lee, W. M., Bonkovsky, H. L., & Dienstag, J. L. (2010). Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Gastroenterology. https://doi.org/10.1053/j.gastro.2009.10.031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.